Company Analysis
Sign in

AstraZeneca PLC (AZN)

NYSE: AZN · Pharmaceutical Preparations · Cambridge · filing with the SEC since 1995
Full chart Alerts Compare
Grade6.8
◀ Past 7.8● Present 7.0▶ Future 5.5
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

347 patents granted to the 8 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to AstraZeneca PLC’s names, not what it holds today.

Patents granted
347
337 utility, 5 design, 5 reissue, 1976 to Dec 31, 2025
Granted in 2025
17
Against 17 in 2024 and 17 in 2023
Applications published
493
36 of them in 2025
Names they are printed under
8
a subsidiary, its holding company
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals54
Medical technology19
Biotechnology12
Analysis of biological materials5
Organic fine chemistry3
Chemical engineering2
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name8 counted
Alexion Pharmaceuticals, Inc. a subsidiary
US, as the owner printed on each patent. 1 more under the same name are not counted (printed in GB)
199 granted
129 published
AstraZeneca UK Limited a subsidiary
GB, as the owner printed on each patent. 1 more under the same name are not counted (printed in SE)
110 granted
75 published
Alexion Pharmaceuticals, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
184 published
AstraZeneca Pharmaceuticals LP a subsidiary
US, as the owner printed on each patent
38 granted
39 published
AstraZeneca UK Limited a subsidiary
named as the applicant on its applications, in GB. 3 more under the same name are not counted (printed in US, printed in UK)
0 granted
47 published
AstraZeneca Pharmaceuticals LP a subsidiary
named as the applicant on its applications, in US
0 granted
15 published
ASTRAZENECA INTELLECTUAL PROPERTY its holding company
GB, as the owner printed on each patent; a holding company under the name ASTRAZENECA PLC. 2 more under the same name are not counted (printed in AU)
0 granted
3 published
ALEXION PHARMA INTERNATIONAL OPERATIONS LIMITED a subsidiary
IE, as the owner printed on each patent
0 granted
1 published
Names not counted (10)
ASTRAZENECA PLC
Most of its patents print SE; this name counts in GB. 1,500 granted and 1,425 published under it are not counted.
ASTRAZENECA PLC
Most of its patents print SE; this name counts in GB. 0 granted and 597 published under it are not counted.
ASTRAZENECA PLC
Most of its patents print SE; this name counts in GB. 22 granted and 26 published under it are not counted.
ASTRAZENECA PLC
No country is printed for it. 0 granted and 23 published under it are not counted.
ASTRAZENECA PLC
No country is printed for it. 0 granted and 13 published under it are not counted.
ASTRAZENECA PLC
No country is printed for it. 0 granted and 4 published under it are not counted.
ASTRAZENECA PLC
Most of its patents print SE; this name counts in GB. 2 granted and 1 published under it are not counted.
AstraZeneca UK Limited
No country is printed for it. 0 granted and 1 published under it are not counted.
AstraZeneca UK Limited
No country is printed for it. 0 granted and 1 published under it are not counted.
AstraZeneca UK Limited
No country is printed for it. 0 granted and 1 published under it are not counted.
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 16, 202512,497,445Monovalent anti-properdin antibodies and antibody fragmentsPharmaceuticalsAlexion Pharmaceuticals, Inc.
Dec 2, 202512,486,316Antibodies that bind the spike protein of SARS-CoV-2BiotechnologyAstraZeneca UK Limited
Nov 4, 202512,462,914Systems and methods for dispensing a statin medication over the counterMedical technologyAstraZeneca UK Limited
Nov 4, 202512,462,905Systems and methods for dispensing a statin medication over the counterMedical technologyAstraZeneca UK Limited
Nov 4, 202512,460,012Dosage and administration of anti-C5 antibodies for treatment of atypical hemolytic uremic syndrome (aHUS) in pediatric patientsPharmaceuticalsAlexion Pharmaceuticals, Inc.
Nov 4, 202512,459,992Methods for treatment of refractory generalized myasthenia gravisPharmaceuticalsAlexion Pharmaceuticals, Inc.
Oct 7, 202512,433,938Alkaline phosphatase polypeptides and methods of use thereofPharmaceuticalsAlexion Pharmaceuticals, Inc.
Sep 30, 202512,428,484Anti-ALK2 antibodies and uses thereofPharmaceuticalsAlexion Pharmaceuticals, Inc.
Sep 2, 202512,404,320Dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH) in pediatric patientsPharmaceuticalsAlexion Pharmaceuticals, Inc.
Aug 26, 202512,398,387Compositions and methods for preparing factor Xa and derivativesBiotechnologyAlexion Pharmaceuticals, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Nov 27, 20252025/0360222COMBINATION OF ANTIBODY-DRUG CONJUGATE AND BISPECIFIC CHECKPOINT INHIBITORPharmaceuticalsAstraZeneca UK Limited
Nov 13, 20252025/0346585PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERSOrganic fine chemistryAlexion Pharmaceuticals, Inc.
Sep 25, 20252025/0298033HIGH SENSITIVITY BIOTINYLATED PEPTIDE BINDING ELISA ASSAYAnalysis of biological materialsAlexion Pharmaceuticals, Inc.
Sep 25, 20252025/0296966COMBINATION OF AN ANTIBODY SPECIFIC FOR A TUMOR ANTIGEN AND A CD47 INHIBITORPharmaceuticalsAstraZeneca UK Limited
Sep 18, 20252025/0289871SARS-COV-2 ANTIBODIES AND METHODS OF USING THE SAMEBiotechnologyAstraZeneca UK Limited
Sep 18, 20252025/0288687COMBINATION OF ANTIBODY-DRUG CONJUGATES AND DNMT INHIBITORSPharmaceuticalsAstraZeneca UK Limited
Sep 4, 20252025/0276079COMBINATION OF ANTIBODY-DRUG CONJUGATE WITH EZH1 and/or EZH2 INHIBITORPharmaceuticalsAstraZeneca UK Limited
Aug 21, 20252025/0263687POLYNUCLEOTIDE PURIFICATION WITH MONOLITH COLUMNSBiotechnologyAlexion Pharmaceuticals, Inc.
Jul 31, 20252025/0243264DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATMENT OF GENERALIZED MYASTHENIA GRAVISPharmaceuticalsAlexion Pharmaceuticals, Inc.
Jul 3, 20252025/0213562METHODS FOR TREATING LYMPHOMAPharmaceuticalsAlexion Pharmaceuticals, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 53 · Biotechnology 8 · Medical technology 6 · Analysis of biological materials 4 · Organic fine chemistry 4 · Measurement 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton AZN · research, not advice